Track market-moving stories before they get noisy

LOWELL, Ark.--(BUSINESS WIRE)--J.B. Hunt Transport Services, Inc.'s (NASDAQ: JBHT) Executive Vice President of Sales and Marketing Spencer Frazier and Senior Vice President of Operations for Intermodal Bill Dietrich will address the Wells Fargo 16th Annual Industrials and Materials Conference in Chicago, Illinois, at 9:45 a.m. EDT on Tuesday, June 9, 2026. Investors may access the live presentation by visiting the Investor Relations section of our website. The presentation replay will also be a.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: JB Hunt (JBHT - Free Report) J.B. Hunt Transport Services is a provider of a wide range of transportation, brokerage, and delivery services to a diverse group of customers through the United States, Canada and Mexico. Founded in 1961, JBHT is based in Lowell, AR. J.B. Hunt's fiscal year coincides with the calendar year. As of Dec 31, 2025, JBHT had 31,750 employees, which consisted of 21,554 company drivers, 8,481 office personnel, 1,374 maintenance technicians, and 341 delivery and material assistants.

JBHT is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Transportation stock. JBHT has a Momentum Style Score of B, and shares are up 16.1% over the past four weeks.

Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.12 to $7.27 per share. JBHT also boasts an average earnings surprise of +6.3%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, JBHT should be on investors' short list.

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at JB Hunt (JBHT - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. JB Hunt currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market? In order to see if JBHT is a promising momentum pick, let's examine some Momentum Style elements to see if this trucking and logistics company holds up.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.

For JBHT, shares are up 3.08% over the past week while the Zacks Transportation - Truck industry is up 3.48% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 19.7% compares favorably with the industry's 26.28% performance as well.

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of JB Hunt have increased 42.15% over the past quarter, and have gained 103.45% in the last year. In comparison, the S&P 500 has only moved 10.22% and 24.7%, respectively.

Investors should also pay attention to JBHT's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. JBHT is currently averaging 987,446 shares for the last 20 days.

Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with JBHT.

Over the past two months, 8 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost JBHT's consensus estimate, increasing from $7.19 to $7.27 in the past 60 days. Looking at the next fiscal year, 9 estimates have moved upwards while there have been no downward revisions in the same time period.

Bottom LineTaking into account all of these elements, it should come as no surprise that JBHT is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep JB Hunt on your short list.

Key Takeaways J.B. Hunt has surged 103.8% in the past year, outperforming the transportation-truck industry.JBHT earnings estimates have moved higher, signaling growing confidence in its outlook.JBHT's efforts to offer sustainable, environment-friendly solutions for customers are commendable. J.B. Hunt Transportation (JBHT - Free Report) performed well in the past year and has the potential to sustain the momentum in the future. If you have not taken advantage of its share price appreciation yet, it’s time to do so.

Against this backdrop, let’s look at the factors that make this stock an attractive pick.

What Makes JBHT an Attractive Pick?An Outperformer: A glimpse at the company’s price trend reveals that the stock has had an impressive run over the past year. Shares of JBHT have surged 103.8% in the past year, outperforming the 73.2% increase of the transportation-truck industry it belongs to.

JBHT Stock’s One-Year Price Comparison Image Source: Zacks Investment Research

Solid Zacks Rank: JBHT presently carries a Zacks Rank #2 (Buy). Our research shows that stocks with a Zacks Rank #1 (Strong Buy) or 2 offer the best investment opportunities. Thus, the company is a compelling investment proposition at the moment.

Northward Estimate Revisions:The direction of estimate revisions serves as an important pointer when it comes to the price of a stock. The Zacks Consensus Estimate for second-quarter 2026 earnings has moved 1.19% north in the past 60 days. For the current year, the consensus mark for earnings has been revised 1.11% upward in the same time frame. The favorable estimate revisions indicate brokers’ confidence in the stock.

Image Source: Zacks Investment Research

Positive Earnings Surprise History: JBHT has an impressive earnings surprise history. The company’s earnings surpassed the Zacks Consensus Estimate in three of the last four quarters (missed the mark in the remaining quarter), delivering an average beat of 6.31%.

Image Source: Zacks Investment Research

Earnings Expectations: Earnings growth and stock price gains often indicate a company’s prospects. For second-quarter 2026, JBHT’s earnings are expected to improve 29.77% year over year. For 2026 and 2027, the company’s earnings are expected to improve 18.79% and 24.41% year over year, respectively.

Growth Factors: J.B. Hunt’s efforts to provide sustainable, environment-friendly solutions for customers are commendable. JBHT has been consistently rewarding its shareholders through dividends and share buybacks. In the first quarter of 2026, JBHT repurchased about 383,000 shares for approximately $80 million, leaving roughly $888 million under its repurchase authorization. Such shareholder-friendly initiatives should boost investor confidence and positively impact the bottom line. Declining operating expenses also have the potential to boost the bottom line.

Other Stocks to ConsiderInvestors interested in the Zacks Transportation sector may consider International Seaways (INSW - Free Report) and Expeditors International of Washington, Inc. (EXPD - Free Report) . 

INSW currently sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

INSW has an expected earnings growth rate of more than 100% for the current year. The company has an encouraging earnings surprise history. Its earnings topped the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 33.93%.

EXPD currently carries a Zacks Rank #2.

Expeditors has an expected earnings growth rate of 11.9% for the current year.  The company has an encouraging earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 13.96%.

Key Takeaways PACB launched a joint FFPE workflow with Covaris to improve the sequencing of archived tumor samples.The solution enhances DNA recovery, boosting structural variant detection and mutation phasing accuracy.PACB sees growth potential as workflow expands use of HiFi sequencing in research and clinical settings. PacBio (PACB - Free Report) recently announced a new joint workflow with Covaris, a PerkinElmer company and leader in sample preparation technologies, aimed at enabling highly accurate HiFi long-read sequencing from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The integrated solution combines Covaris’ advanced extraction technology with PacBio’s library preparation and Revio sequencing system, helping overcome long-standing challenges related to DNA damage and fragmentation in archived clinical samples.

The development significantly expands the usability of FFPE samples, which are widely available and critical for cancer research. By delivering higher-quality sequencing data, improved structural variant detection and direct mutation phasing, the workflow positions PacBio to unlock valuable insights from previously underutilized tumor archives and strengthen its role in advancing oncology research.

Likely Trend of PACB Stock Following the NewsShares of PACB have gained 1.9% since the announcement on Thursday. In the year-to-date period, shares of the company lost 12.8% compared with the industry’s 11.4% decline.  The S&P 500 increased 2.8% in the same time frame.

This joint workflow is likely to strengthen PacBio’s long-term growth by expanding the addressable market for its HiFi sequencing platforms, particularly into the vast backlog of FFPE clinical samples that were previously difficult to analyze. By enabling high-quality long-read sequencing from these archived tissues, PacBio can drive higher adoption of its Revio system in both research and clinical settings, increasing instrument utilization and recurring consumables revenue.

PACB currently has a market capitalization of $483.2 million.

Image Source: Zacks Investment Research

More on the NewsA key highlight of the joint workflow is its ability to recover longer DNA fragments, up to 5,000 base pairs, from heavily degraded FFPE samples using Covaris’ Adaptive Focused Acoustics-based truXTRAC extraction technology. These fragments are then processed through PacBio’s Kinnex library preparation, which concatenates shorter DNA pieces into longer molecules optimized for HiFi sequencing on the Revio system. This integrated approach not only improves sequencing efficiency but also ensures higher data quality, addressing a major limitation that has historically restricted the use of FFPE samples in long-read sequencing.

Importantly, performance data underscores the workflow’s potential impact. Across multiple tumor types, including brain, kidney and uterine samples, the solution generated more than 100 million HiFi reads per sample, with mean read lengths ranging from 750 to 1,500 base pairs. This enabled detection of more than 11,000 structural variants and over 5 million small variants per sample, with roughly 60% of variants directly phased into haplotypes. Compared to traditional short-read sequencing, which typically identifies fewer structural variants and relies on indirect phasing methods, this workflow delivers deeper and more actionable genomic insights, making it particularly valuable for complex cancer research applications.

Favorable Industry Prospect for PACBPer a report by Grand View Research, the global long-read sequencing market size was estimated at $538.9 million in 2024 and is projected to reach $1.53 billion by 2030, expanding at a CAGR of 20.12% from 2025 to 2030.

The major factors driving market growth include the increasing prevalence of genetic diseases like cancers and chromosomal disorders.

Recent Developments by PACBIn March, PACB announced that Basecamp Research has selected its HiFi sequencing technology on the Revio system to support the ambitious Trillion Gene Atlas initiative.

The collaboration highlights the growing importance of high-accuracy, long-read sequencing in powering next-generation AI-driven drug discovery. By preserving full genomic context, PacBio’s HiFi sequencing is expected to enable more precise biological insights and improve the training of foundation models like Basecamp’s EDEN platform, ultimately accelerating the design of novel therapeutics at scale.

PACB’s Zacks Rank & Other Key PicksCurrently, PACB sports a Zacks Rank #1 (Strong Buy).

Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Cardinal Health (CAH - Free Report) .

Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.

GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.

Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.

Key Takeaways PACB partners with Lucid Genomics to enhance tertiary analysis for HiFi sequencing workflows.PACB integrates Lucid's platform to streamline variant detection, interpretation and reporting.PacBio aims to reduce workflow complexity and accelerate insights, supporting broader adoption. PacBio (PACB - Free Report) recently announced a compatibility collaboration with Lucid Genomics, bringing the latter into its Compatible partner program to strengthen tertiary analysis capabilities for long-read sequencing. The move expands PacBio’s ecosystem by enabling seamless integration of Lucid’s bioinformatics platform with its HiFi sequencing technology, helping users translate raw sequencing data into meaningful biological and clinical insights more efficiently.

The partnership is aimed at simplifying downstream analysis workflows, covering everything from variant detection and annotation to interpretation and reporting. By offering a validated, end-to-end pipeline optimized for HiFi data, the collaboration is expected to reduce integration complexity for labs and accelerate time to actionable insights, supporting broader adoption of PacBio’s long-read sequencing solutions across research and clinical settings.

Likely Trend of PACB Stock Following the NewsShares of PACB have gained 1.9% in yesterday’s after-market trading since the announcement. In the year-to-date period, shares of the company lost 7.5% compared with the industry’s 11.1% decline.  The S&P 500 increased 4% in the same time frame.

This collaboration strengthens PacBio’s long-term business by deepening its ecosystem and making its HiFi sequencing platform more user-friendly. By integrating a validated tertiary analysis solution, PacBio reduces a key friction point in the workflow, making it easier for labs to move from sequencing to actionable insights. This improves customer retention, attracts new users, especially in clinical and translational research and enhances the overall value proposition of its systems.

PACB currently has a market capitalization of $525.5 million.

Image Source: Zacks Investment Research

More on the NewsTertiary analysis represents a critical step in the sequencing workflow, where processed genomic data is translated into biological and clinically relevant insights. It enables streamlined annotation, interpretation and reporting of genomic variants, helping researchers derive real value from sequencing data and better understand the genetic basis of disease. In this context, the collaboration underscores the interoperability of Lucid Genomics’ platform with PacBio’s HiFi sequencing, allowing users to convert long-read data into actionable insights more efficiently. From variant calling and structural variant detection to comprehensive clinical interpretation, Lucid offers a unified workflow optimized for the accuracy and throughput of HiFi reads.

PacBio’s Compatible partner program plays a central role in this integration by validating third-party solutions that work seamlessly with its instruments and data formats. With Lucid Genomics now part of this ecosystem, customers gain access to a robust set of downstream analysis tools tailored for long-read sequencing. The platform supports a wide range of functionalities, including alignment, phasing, variant annotation, methylation analysis and visualization—all designed to fully leverage the depth and precision of HiFi sequencing. This enables labs to adopt a streamlined, end-to-end pipeline that connects sequencing output directly to research or clinical reporting.

Another important aspect is the focus on scalability and ease of adoption. Lucid Genomics’ cloud-native platform offers a production-ready solution that reduces integration challenges while ensuring compatibility with PacBio data standards. This lowers technical barriers for labs of different sizes and accelerates time to insight. Additionally, both companies plan to collaborate on joint customer engagements, technical enablement and co-marketing initiatives, which should help expand the global footprint of HiFi sequencing and further strengthen PacBio’s partner-driven ecosystem strategy.

Favorable Industry Prospect for PACBPer a report by Grand View Research, the global long-read sequencing market size was estimated at $538.9 million in 2024 and is projected to reach $1.53 billion by 2030, expanding at a CAGR of 20.12% from 2025 to 2030.

The major factors driving market growth include the increasing prevalence of genetic diseases like cancers and chromosomal disorders.

A Recent Development by PACBIn March, PACB announced that Basecamp Research has selected its HiFi sequencing technology on the Revio system to support the ambitious Trillion Gene Atlas initiative.

The collaboration highlights the growing importance of high-accuracy, long-read sequencing in powering next-generation AI-driven drug discovery. By preserving full genomic context, PacBio’s HiFi sequencing is expected to enable more precise biological insights and improve the training of foundation models like Basecamp’s EDEN platform, ultimately accelerating the design of novel therapeutics at scale.

PACB’s Zacks Rank & Key PicksCurrently, PACB carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Cardinal Health (CAH - Free Report) .

Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.

GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.

Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.

Posted by Defense World Staff on Apr 27th, 2026

Autonomix Medical (NASDAQ:AMIX – Get Free Report) and Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Profitability This table compares Autonomix Medical and Pacific Biosciences of California’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Autonomix Medical N/A -228.82% -186.65% Pacific Biosciences of California -341.47% -326.43% -19.40% Analyst Ratings This is a summary of recent recommendations and price targets for Autonomix Medical and Pacific Biosciences of California, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autonomix Medical 1 1 1 0 2.00 Pacific Biosciences of California 2 2 1 0 1.80 Autonomix Medical presently has a consensus price target of $2.00, suggesting a potential upside of 442.89%. Pacific Biosciences of California has a consensus price target of $1.67, suggesting a potential upside of 6.84%. Given Autonomix Medical’s stronger consensus rating and higher possible upside, research analysts plainly believe Autonomix Medical is more favorable than Pacific Biosciences of California.

Volatility & Risk Autonomix Medical has a beta of -2.48, indicating that its share price is 348% less volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500.

Insider & Institutional Ownership 10.8% of Autonomix Medical shares are held by institutional investors. 6.2% of Autonomix Medical shares are held by insiders. Comparatively, 2.4% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings This table compares Autonomix Medical and Pacific Biosciences of California”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Autonomix Medical N/A N/A -$11.41 million ($3.55) -0.10 Pacific Biosciences of California $160.01 million 3.03 -$546.38 million ($1.84) -0.85 Autonomix Medical has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Summary Autonomix Medical beats Pacific Biosciences of California on 8 of the 12 factors compared between the two stocks.

About Autonomix Medical (Get Free Report)

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

About Pacific Biosciences of California (Get Free Report)

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEContrasting LuxUrban Hotels (NASDAQ:LUXH) and Yangtze River Port and Logistics (OTCMKTS:YRIV)

NEXT HEADLINE »Financial Contrast: Molson Coors Beverage (NYSE:TAP) & Brown Forman (NYSE:BF.A)

May 07, 2026 16:05 ET  | Source: PacBio

MENLO PARK, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2026.

Recent Business Highlights

Selected by Basecamp Research to power its Trillion Gene Atlas, which is expected to result in approximately 100,000 samples being deeply sequenced from over 31 countriesAnnounced a collaboration with DNAstack to power the first global federated HiFi whole genome datasetExpanded SPRQ-Nx beta program to more customers domestically and internationally after receiving positive feedback from initial usersEMEA revenue grew by 17% year-over-year as a result of increased consumables demand reflecting both account expansion and higher utilization, particularly in clinical settingsNamed Lucid Genomics as a PacBio Compatible partner for tertiary analysis of data generated on PacBio's long-read sequencing instrumentsCompleted sale of short-read sequencing assets for net cash proceeds of approximately $48.1 million, strengthening the balance sheet and extending cash runway “We continue to see increasing clinical adoption of HiFi which contributed to another record quarter for consumable revenue. However, instrument revenue, particularly Vega, was lower than we had expected," said Christian Henry, President and Chief Executive Officer. "Nonetheless, we made significant progress on several important initiatives, such as our expansion of the SPRQ-Nx beta program based on the positive early feedback on the new chemistry. Based on this success, we plan to execute a broad commercial rollout to all Revio customers later this month, which we believe will further catalyze consumable growth and Revio instrument demand. Additionally, we continue to prove our ability to win large-scale projects as we were selected by Basecamp Research to power the Trillion Gene Atlas, which has the potential to produce the largest and most diverse high-fidelity metagenomic dataset in the world."

First quarter results:

 Q12026Q12025Revenue(in millions)$37.2$37.2Consumable revenue(in millions)$21.8$20.1Instrument revenue(in millions)$9.7$11.0Service and other revenue(in millions)$5.6$6.0Revio™system placements1512Vega™system placements2728Annualized Revio pull-through per system~$229,000~$236,000Ending cash, cash equivalents, and investments(in millions)$276.0$343.1 Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP measures at the end of this release.

We recorded a GAAP gross profit of $12.8 million during the first quarter of 2026 compared to a GAAP gross loss of $1.4 million during the first quarter of 2025. GAAP gross loss for the first quarter of 2025 reflected charges related to our restructuring announced April 9, 2025 and included $7.7 million in restructuring-related inventory charges, $4.3 million of amortization of acquired intangible assets, and a $4.1 million loss on purchase commitments. Non-GAAP gross profit for the first quarter of 2026 was $13.8 million compared to non-GAAP gross profit of $15.0 million for the first quarter of 2025. GAAP gross margin was 35% for the first quarter of 2026 compared to a negative GAAP gross margin of 4% for the first quarter of 2025. Non-GAAP gross margin was 37% for the first quarter of 2026 compared to a non-GAAP gross margin of 40% for the first quarter of 2025. The decline in Non-GAAP gross margin was primarily driven by increased computing component costs, temporary first quarter promotions for Vega and inventory and warranty-related adjustments and charges.

GAAP operating expenses totaled $21.2 million for the first quarter of 2026, compared to $427.6 million for the first quarter of 2025. GAAP operating expenses for the first quarter of 2026 included $16.3 million of litigation settlement charges and related legal fees, and a gain on disposal of assets of approximately $45.8 million. GAAP operating expenses for the first quarter of 2025 include $381.8 million of charges associated with the Company’s restructuring efforts and re-focus on its long-read business, partially offset by an $18.7 million decrease in the change in the fair value of contingent consideration. Non-GAAP operating expenses totaled $49.9 million for the first quarter of 2026, compared to $61.7 million for the first quarter of 2025. GAAP and non-GAAP operating expenses for the first quarter of 2026 and the first quarter of 2025 included non-cash share-based compensation of $3.8 million and $8.0 million, respectively.

GAAP net loss for the first quarter of 2026 was $8.3 million, compared to $426.1 million for the first quarter of 2025. Non-GAAP net loss for the first quarter of 2026 was $35.9 million, compared to $44.4 million for the first quarter of 2025.

GAAP net loss per share for the first quarter of 2026 was $0.03, compared to $1.44 for the first quarter of 2025. Non-GAAP net loss per share for the first quarter of 2026 was $0.12, compared to $0.15 for the first quarter of 2025.

2026 Financial Outlook

PacBio expects revenue for the full year 2026 to be in the range of $165 million to $175 million.

Quarterly Conference Call Information

Management will host a quarterly conference call today at 4:30 p.m. Eastern Time to review financial results for the first quarter ended March 31, 2026. Investors can access the call by dialing 1-888-349-0136 (or 1-412-317-0459 for international callers) and requesting to join the “PacBio Q1 Earnings Call". The call will be webcast live and available for replay at PacBio's website at https://investor.pacificbiosciences.com. 

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which primarily consist of our HiFi long-read sequencing systems, address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Statement regarding use of non‐GAAP financial measures

PacBio reports non‐GAAP results for basic net income and loss per share, net income, net loss, gross margins, gross profit (loss) and operating expenses in addition to, and not as a substitute for, or because it believes that such information is superior to, financial measures calculated in accordance with GAAP. PacBio believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of PacBio’s non-GAAP financial measures as tools for comparison.

PacBio's financial measures under GAAP include substantial charges that are listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. PacBio excludes recurring charges from its non-GAAP financial statements, including amortization of acquired intangible assets and changes in fair value of contingent consideration, and further excludes infrequent and limited charges including impairment charges, restructuring-related expenses for discrete restructuring events, settlement charges, disposition of short-read assets, benefits from income taxes and other adjustments and rounding differences.

Management has excluded the effects of these items in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance. In addition, management uses non-GAAP measures to compare PacBio’s performance relative to forecasts and strategic plans and to benchmark its performance externally against competitors.

PacBio encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation of PacBio’s non-GAAP financial measures to their most directly comparable financial measure stated in accordance with GAAP has been provided in the financial statement tables included in this press release. PacBio is unable to reconcile future-looking non-GAAP guidance without unreasonable effort because certain items that impact this measure are out of PacBio's control and/or cannot be reasonably predicted at this time.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, statements relating to PacBio’s initiatives as well as the expected financial impact and timing of these plans and initiatives, including our expectations regarding SPRQ-Nx; PacBio’s financial guidance and expectations for future periods; new and continued reception of PacBio’s products and their expansion into new or existing markets; our expectations regarding our collaboration with Basecamp Research; developments affecting our industry and the markets in which we compete, including the impact of new products and technologies and tariffs; anticipated results of studies and future customer use and costs of our products and consumables, including the increasing clinical adoption of HiFi; and the availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies. Reported results and orders for any instrument system should not be considered an indication of future performance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, but not limited to, challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales; potential cancellation of existing instrument orders; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers; risks related to PacBio's ability to successfully execute and realize the benefits of acquisitions; the impact of new, increased or enhanced tariffs and export restrictions; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; high costs of computer memory components; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development timelines; the possible loss of key employees, customers, or suppliers; customers and prospective customers curtailing or suspending activities using PacBio's products; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; risks associated with international operations; and other risks associated with general macroeconomic conditions and global economic or political instability, including war and other international conflicts, such as the conflicts in the Middle East. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

The unaudited condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in PacBio's Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission.

Contacts

Investors:

[email protected] 

Media:
[email protected] 

Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statements of Operations
  Three Months Ended(in thousands, except per share amounts)March 31,
2026 December 31,
2025 March 31,
2025Revenue:     Product revenue$31,534  $38,965  $31,113 Service and other revenue 5,644   5,680   6,040 Total revenue 37,178   44,645   37,153 Cost of Revenue:     Cost of product revenue(1)(3)(4) 19,972   24,204   26,333 Cost of service and other revenue 4,182   3,681   3,778 Amortization of acquired intangible assets 183   183   4,345 Loss on purchase commitment(1) —   11   4,068 Total cost of revenue 24,337   28,079   38,524 Gross profit (loss) 12,841   16,566   (1,371)Operating Expense:     Research and development(1) 19,608   22,879   29,053 Sales, general and administrative(1)(3) 31,153   34,051   40,168 Impairment charges(2) —   —   15,000 Settlement charges(3) 15,400   —   — Gain on disposal of assets(4) (45,796)  —   — Amortization of acquired intangible assets(5) 833   833   362,042 Change in fair value of contingent consideration(6) —   —   (18,700)Total operating expense 21,198   57,763   427,563 Operating loss (8,357)  (41,197)  (428,934)Interest expense (1,740)  (1,740)  (1,737)Other income, net 2,006   2,768   4,294 Loss before income taxes (8,091)  (40,169)  (426,377)Income tax provision (benefit) 184   202   (302)Net loss$(8,275) $(40,371) $(426,075)      Net loss per share:     Basic$(0.03) $(0.13) $(1.44)Diluted$(0.03) $(0.13) $(1.44)      Weighted average shares outstanding used in calculating net loss per share:     Basic 305,819   301,907   296,858 Diluted 305,819   301,907   296,858  (1)  Balances for the three months ended December 31, 2005 and March 31, 2025 include restructuring costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.

(2)  In-process research and development ("IPR&D") impairment charge was driven primarily by macroeconomic factors and restructuring initiatives, including the focus on long-read innovation, resulting in changes to the timing and amounts of cash flows.

(3)  Includes litigation settlement charges and related legal fees in connection with the binding term sheet entered into with Personal Genomics of Taiwan, Inc during the three months ended March 31, 2026.

(4)  Balances for the three months ended March 31, 2026 Include amounts related to the disposition of short-read assets, including the gain on the sale of certain assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies, and related non-recurring customer transition costs.

(5)  Balance for the three months ended March 31, 2025 includes accelerated amortization of acquired intangible assets related to restructuring initiatives. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.

(6)  Change in fair value of contingent consideration was due to fair value adjustments of a milestone payment payable upon the achievement of a milestone event.

Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets (in thousands) March 31,
2026 December 31,
2025Assets    Cash and investments $275,962 $279,506Accounts receivable, net  29,350  35,448Inventory, net  51,022  49,285Prepaid expenses and other current assets  13,164  10,793Property and equipment, net  24,376  24,146Operating lease right-of-use assets, net  40,846  41,695Restricted cash  1,590  1,552Intangible assets, net  14,104  15,124Goodwill  317,761  317,761Other long-term assets  14,190  8,773Total Assets $782,365 $784,083     Liabilities and Stockholders' Equity    Accounts payable $13,609 $20,770Accrued expenses  33,904  33,646Deferred revenue  19,884  19,865Operating lease liabilities  59,281  57,040Convertible senior notes, net  644,107  645,382Other liabilities  9,214  2,031Stockholders' equity  2,366  5,349Total Liabilities and Stockholders' Equity $782,365 $784,083 Pacific Biosciences of California, Inc.
Reconciliation of Non-GAAP Financial Measures
   Three Months Ended(in thousands, except per share amounts) March 31,
2026 December 31,
2025 March 31,
2025GAAP net loss $(8,275) $(40,371) $(426,075)Change in fair value of contingent consideration(1)  —   —   (18,700)Settlement charges(2)  16,804   —   — Amortization of acquired intangible assets  1,016   1,016   7,128 Disposition of short-read assets(3)  (45,490)  —   — Income tax benefit(4)  —   —   (546)Restructuring(5)  —   1,776   393,788 Non-GAAP net loss $(35,945) $(37,579) $(44,405)       GAAP basic net loss per share $(0.03) $(0.13) $(1.44)Change in fair value of contingent consideration(1)  —   —   (0.06)Settlement charges(2)  0.05   —   — Amortization of acquired intangible assets  —   —   0.02 Disposition of short-read assets(3)  (0.15)  —   — Restructuring(5)  —   0.01   1.33 Other adjustments and rounding differences  0.01   —   — Non-GAAP basic net loss per share $(0.12) $(0.12) $(0.15)       GAAP gross profit (loss) $12,841  $16,566  $(1,371)Amortization of acquired intangible assets  183   183   4,345 Settlement charges(2)  500   —   — Disposition of short-read assets(3)  306   —   — Restructuring(5)  —   1,072   12,027 Non-GAAP gross profit $13,830  $17,821  $15,001        GAAP gross profit (loss) %  35%  37% (4)%       Non-GAAP gross profit %  37%  40%  40%       GAAP total operating expense $21,198  $57,763  $427,563 Change in fair value of contingent consideration(1)  —   —   18,700 Settlement charges(2)  (16,304)  —   — Amortization of acquired intangible assets  (833)  (833)  (2,783)Disposition of short-read assets(3)  45,796   —   — Restructuring(5)  —   (704)  (381,761)Non-GAAP total operating expense $49,857  $56,226  $61,719  (1)  Change in fair value of contingent consideration was due to fair value adjustments of a milestone payment payable upon the achievement of a milestone event.

(2)  Includes litigation settlement charges and related legal fees in connection with the binding term sheet entered into with Personal Genomics of Taiwan, Inc.

(3)  Balance includes amounts related to the disposition of short-read assets, including the gain on the sale of certain assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies, and related non-recurring customer transition costs.

(4)  A deferred income tax benefit during the three months ended March 31, 2025 is primarily related to the change in the deferred tax liability balance resulting from the accelerated amortization of acquired intangible assets and impairment of IPR&D.

(5)  Restructuring-related costs incurred in connection with the 2025 plan during the three months ended December 31, 2025 and March 31, 2025 consist primarily of costs included in cost of revenue related to excess inventory and purchase commitment losses, as well as costs included in operating expenses related to employee separation, accelerated depreciation, IPR&D impairment, and accelerated amortization of acquired intangibles.

Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 322

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

SAN FRANCISCO--(BUSINESS WIRE)--Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology.

May 21, 2026 16:05 ET  | Source: PacBio

MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies’ Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.

A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:
[email protected]

Media:
[email protected]

PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.

Key Takeaways PacBio gains from product development and a Q1 earnings beat despite funding challenges.PACB's SPRQ-Nx chemistry boosts yields and targets sub-$300 genome sequencing at scale.PacBio sees research funding uncertainty weighing on Revio and Vega demand through 2026. Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong first-quarter results, is expected to contribute further. However, concerns about funding headwinds persist.

In the year-to-date period, this Zacks Rank #2 (Buy) company’s shares have lost 17.6% compared with 16.7% decline of the industry. The S&P 500 Composite has improved 11% in the said time frame.

The renowned global provider of sequencing systems has a market capitalization of $490.8 million. The company projects 22.6% growth for 2026 and expects to maintain its strong performance going forward. PacBio’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average surprise of 29.8%.

Image Source: Zacks Investment Research

Factors Favoring PACB’s GrowthSequencing Technologies Strengthen Market Leadership: PacBio differentiates itself in the genomics industry through its proprietary HiFi long-read sequencing, based on Single-Molecule Real-Time (SMRT) technology. This technology enables the high-accuracy, real-time detection of complex genomic structures, such as structural variations, haplotypes and epigenetic modifications.

Per a report by Data Bridge Market Research, the global SMRT market size was valued at $2.88 billion in 2024 and is projected to reach $4.36 billion by 2032, at a CAGR of 5.3%. Additionally, PacBio has expanded its offerings by integrating Sequencing by Binding chemistry with the launch of its Onso system in 2022, a short-read platform delivering ≥90% of bases at Q40+ accuracy, 15 times more precise than traditional sequencing methods. By providing both long-read and short-read technologies, PacBio uniquely serves diverse research and clinical applications while driving down costs and enhancing variant detection.

Robust Product Portfolio Driving Growth: PacBio continues to strengthen its competitive position through innovation in its HiFi sequencing platform. The company's SPRQ-Nx chemistry is gaining traction, delivering higher sequencing yields and enabling human whole-genome sequencing costs below $300 at scale through reusable SMRT Cells. Management plans to extend the technology to the Vega platform later this year, enhancing throughput and workflow efficiency.

PacBio is also advancing its next-generation ultra-high-throughput sequencing platform to target large-scale clinical and population genomics opportunities. Additionally, its collaboration with Basecamp Research to sequence roughly 100,000 metagenomic samples highlights the expanding role of HiFi sequencing in AI-driven biological research and underscores the technology's growing adoption across emerging applications.

Strong Q1 Results: PacBio exited the first quarter of 2026 with mixed results, wherein earnings beat the Zacks Consensus Estimate while revenues missed the same. Stable top-line performance, despite softer instrument sales, reflected continued strength in consumables demand and improving utilization trends across the installed base.

Growth in consumables revenues, expansion across the EMEA region and disciplined expense management were encouraging. The company also reported a significantly narrower operating loss year over year, supported by lower operating expenses and continued restructuring benefits.

A Factor That May Offset the Gains for PACBFunding Headwinds Continue to Weigh on Instrument Demand: PacBio continues to face funding-related headwinds that are weighing on instrument demand, particularly across academic and government research markets. Uncertainty around grant funding and cautious capital spending have pressured purchases of both Revio and Vega systems, with Vega being more exposed to academic budget constraints.

While the company is seeing growing interest from clinical and commercial customers, management does not anticipate a meaningful recovery in research funding through 2026 and recently lowered the high end of its annual revenue outlook due in part to weaker instrument demand. Although the upcoming commercial launch of SPRQ-Nx chemistry could improve the attractiveness of PacBio’s sequencing platforms by lowering costs and boosting throughput, near-term instrument growth is expected to remain dependent on expanding clinical adoption rather than a broad recovery in research spending.

Estimate TrendPacBio has been witnessing a positive estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for its adjusted loss per share has narrowed by 13 cents to 41 cents.

The Zacks Consensus Estimate for 2026 revenues is pegged at $165.8 million, indicating a 3.6% increase from the year-ago reported numbers.

Other Key PicksSome other top-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Guidewire (NYSE: GWRE) today released the latest edition of its annual study of insurance customers in Europe, revealing their attitudes towards insurers' use of artificial intelligence (AI) and identifying opportunities for insurers to continue earning their trust.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520571278/en/

The 2026 Guidewire European Insurance Consumer Surveyfound that UK customers feel positive about insurers using AI provided there is human oversight and strong safeguards in place. Almost one third (30 percent) said they would be happy with their insurer using AI tools to make decisions about the price of their insurance policy.

When customers can see an advantage in the insurer's use of AI, acceptance rises. For example, 38 percent agree they would be happy with AI assisting them in completing insurance documents and policy applications, and 39 percent are comfortable with AI supporting human call handlers in answering their questions (both figures unchanged from last year’s findings).

With little year-on-year change in customers’ comfort with how insurers use AI, the industry is at a key stage in determining what will be required to further build trust among consumers and advance AI deployment responsibly. UK consumers highlighted three key priorities, including human intervention (33 percent), transparency (26 percent), and third-party regulation to keep the technology in check (23 percent).

The survey also revealed that increased personal use of AI is making customers two times more receptive to its use by insurers:

Daily AI users are twice as likely as the general public to trust automated insurance pricing. While 63 percent of those who use AI tools daily are comfortable with "human-free" policy decisions, only 30 percent of the broader UK population shares that sentiment. 80 percent of daily AI users would be happy for the technology to assist them in filling out insurance documents and completing policy applications, compared with 38 percent of UK consumers overall. More than half (59.5 percent) of those using AI every day are comfortable with the technology deciding and processing insurance claims or determining claim value, compared with 27 percent of UK consumers overall. Even among daily AI users, transparency (30.6 percent) and keeping a human in the loop (39 percent) continue to score highly as prerequisites for trust. Charles Clarke, Group Vice President, Guidewire, said: “AI is playing an increasingly important role in the insurance industry, and customers are becoming more comfortable with its use. Our report shows that when customers clearly see its value, they are significantly more likely to accept AI within the insurance process.

“To further enhance acceptance, customers are calling for greater transparency, regulation, and human oversight. Insurers should work collaboratively with one another, with technology providers, and with regulators to meet these expectations and build lasting trust in how AI is used whether those capabilities come from their core platforms, embedded assistants, or broader AI partners.”

Michael Cook, Partner, PwC, said: “The findings underscore a clear desire among UK customers for a balanced approach to AI in insurance - embracing the efficiencies and convenience it offers, while ensuring that human judgement remains integral to decision-making especially as the use of AI moves beyond delivering efficiency into more value additive work and ultimately, operating differently.

“As AI becomes more embedded in daily life, insurers must prioritise transparency and robust regulation to maintain consumer trust and confidence including the adoption of the appropriate governance and frameworks and exploring the role of AI to 'manage AI'. Striking this balance will be key to unlocking AI’s full potential in delivering fairer, more personalised insurance services and moving to a very different way of operating with a combined people and agent workforce."

About Guidewire

Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. More than 570 insurers in 43 countries, from new ventures to the largest and most complex in the world, rely on Guidewire products. With core systems leveraging data and analytics, digital, and artificial intelligence, Guidewire defines cloud platform excellence for P&C insurers.

We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry’s largest R&D team and SI partner ecosystem. Our marketplace represents the largest partner community in P&C, where customers can access hundreds of applications to accelerate integration, localization, and innovation.

For more information, please visit www.guidewire.com and follow us on X and LinkedIn.

Methodology:

The research was conducted by Censuswide with 4,004 Consumers who have bought or renewed a general insurance product or made a claim under it in the last 12 months across the UK, France, Germany and Spain between 13.01.2026 - 22.01.2026. Censuswide is a member of the Market Research Society (MRS) and the British Polling Council (BPC), and a signatory of the Global Data Quality Pledge. We adhere to the MRS Code of Conduct and ESOMAR principles.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520571278/en/

SAN MATEO, Calif.--(BUSINESS WIRE)--Guidewire (NYSE: GWRE) announced that it will release its financial results for the fiscal quarter ended April 30, 2026 after market close on Thursday, June 4, 2026. On that day, management will host an audio webcast at 2:00 p.m. PT (5:00 p.m. ET) to review and discuss the Company's results for the third quarter fiscal year 2026. The live audio webcast will be accessible to the public through the Investor Relations website at https://ir.guidewire.com/. A repl.

GWRE reports Q3 FY26 on June 4. It guides $352M-$358M revenue as cloud insurance modernization and AI deals lift ARR and margins.

On June 02, 2026, Guidewire Software Inc (GWRE) shares fell 5.1% today, with the stock currently trading at $162.74. Over the past year, GWRE has experienced co

Guidewire Software (GWRE) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.88 per share a year ago.

Although the revenue and EPS for Guidewire Software (GWRE) give a sense of how its business performed in the quarter ended April 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Guidewire Software, Inc. (GWRE) Q3 2026 Earnings Call Transcript

Guidewire Software, Inc. reported another beat-and-raise quarter in Q3, showing continued growth momentum. The market took GWRE's report negatively. ARR growth decelerated, which caused more uncertain future growth expectations. I estimate GWRE stock to have 25% upside to $170 after the stock's post-earnings decline.

Examine the evolution of Guidewire Software's (GWRE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Clean Harbors (CLH) could produce exceptional returns because of its solid growth attributes.

Clean Harbors NYSE: CLH reported better-than-expected first-quarter 2026 results and raised its full-year outlook, citing stronger profitability across both of its operating segments, improved base oil pricing and continued momentum in environmental services.